Literature DB >> 32609312

Class switching and high-affinity immunoglobulin G production by B cells is dispensable for the development of hypertension in mice.

Yuhan Chen1,2, Bethany L Dale2, Matthew R Alexander3, Liang Xiao4, Mingfang Ao4, Arvind K Pandey4, Charles D Smart2, Gwendolyn K Davis4, Meena S Madhur2,3,4,5.   

Abstract

AIMS: Elevated serum immunoglobulins have been associated with experimental and human hypertension for decades but whether immunoglobulins and B cells play a causal role in hypertension pathology is unclear. In this study, we sought to determine the role of B cells and high-affinity class-switched immunoglobulins on hypertension and hypertensive end-organ damage to determine if they might represent viable therapeutic targets for this disease. METHODS AND
RESULTS: We purified serum immunoglobulin G (IgG) from mice exposed to vehicle or angiotensin (Ang) II to induce hypertension and adoptively transferred these to wild type (WT) recipient mice receiving a subpressor dose of Ang II. We found that transfer of IgG from hypertensive animals does not affect blood pressure, endothelial function, renal inflammation, albuminuria, or T cell-derived cytokine production compared with transfer of IgG from vehicle infused animals. As an alternative approach to investigate the role of high-affinity, class-switched immunoglobulins, we studied mice with genetic deletion of activation-induced deaminase (Aicda-/-). These mice have elevated levels of IgM but virtual absence of class-switched immunoglobulins such as IgG subclasses and IgA. Neither male nor female Aicda-/- mice were protected from Ang II-induced hypertension and renal/vascular damage. To determine if IgM or non-immunoglobulin-dependent innate functions of B cells play a role in hypertension, we studied mice with severe global B-cell deficiency due to deletion of the membrane exon of the IgM heavy chain (µMT-/-). µMT-/- mice were also not protected from hypertension or end-organ damage induced by Ang II infusion or deoxycorticosterone acetate-salt treatment.
CONCLUSIONS: These results suggest that B cells and serum immunoglobulins do not play a causal role in hypertension pathology. Published on behalf of the European Society of Cardiology. All rights reserved.
© The Author(s) 2020. For permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  B cells; Blood pressure; Hypertension; Immunity; Inflammation

Mesh:

Substances:

Year:  2021        PMID: 32609312      PMCID: PMC7983008          DOI: 10.1093/cvr/cvaa187

Source DB:  PubMed          Journal:  Cardiovasc Res        ISSN: 0008-6363            Impact factor:   10.787


  32 in total

1.  A new approach to residual risk in treated hypertension--3P screening.

Authors:  Allan D Struthers
Journal:  Hypertension       Date:  2013-06-17       Impact factor: 10.190

2.  Increased serum levels of immunoglobulins in untreated and treated essential hypertension. I. Relation to blood pressure.

Authors:  B O Kristensen
Journal:  Acta Med Scand       Date:  1978

3.  CD70 Exacerbates Blood Pressure Elevation and Renal Damage in Response to Repeated Hypertensive Stimuli.

Authors:  Hana A Itani; Liang Xiao; Mohamed A Saleh; Jing Wu; Mark A Pilkinton; Bethany L Dale; Natalia R Barbaro; Jason D Foss; Annet Kirabo; Kim R Montaniel; Allison E Norlander; Wei Chen; Ryosuke Sato; L Gabriel Navar; Simon A Mallal; Meena S Madhur; Kenneth E Bernstein; David G Harrison
Journal:  Circ Res       Date:  2016-03-17       Impact factor: 17.367

4.  Increased serum IgG levels in essential hypertension.

Authors:  P Suryaprabha; T Padma; U B Rao
Journal:  Immunol Lett       Date:  1984       Impact factor: 3.685

5.  Raised serum IgG levels in hypertension.

Authors:  A Ebringer; A E Doyle
Journal:  Br Med J       Date:  1970-04-18

6.  Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015.

Authors: 
Journal:  Lancet       Date:  2016-10-08       Impact factor: 79.321

Review 7.  B cells and humoral immunity in atherosclerosis.

Authors:  Dimitrios Tsiantoulas; Cody J Diehl; Joseph L Witztum; Christoph J Binder
Journal:  Circ Res       Date:  2014-05-23       Impact factor: 17.367

8.  Critical role of activation induced cytidine deaminase in experimental autoimmune encephalomyelitis.

Authors:  Yonglian Sun; Ivan Peng; Kate Senger; Kajal Hamidzadeh; Mike Reichelt; Miriam Baca; Ronald Yeh; Maria N Lorenzo; Andrew Sebrell; Christopher Dela Cruz; Lucinda Tam; Racquel Corpuz; Jiansheng Wu; Tao Sai; Merone Roose-Girma; Søren Warming; Mercedesz Balazs; Lino C Gonzalez; Patrick Caplazi; Flavius Martin; Jason Devoss; Ali A Zarrin
Journal:  Autoimmunity       Date:  2013-01-18       Impact factor: 2.815

9.  Critical role of Interleukin 21 and T follicular helper cells in hypertension and vascular dysfunction.

Authors:  Bethany L Dale; Arvind K Pandey; Yuhan Chen; Charles D Smart; Fanny Laroumanie; Mingfang Ao; Liang Xiao; Anna E Dikalova; Sergey I Dikalov; Fernando Elijovich; Jason D Foss; Natalia R Barbaro; Justin P Van Beusecum; Serpil M Deger; Aseel Alsouqi; Hana A Itani; Allison E Norlander; Matthew R Alexander; Shilin Zhao; T Alp Ikizler; Holly M Scott Algood; Meena S Madhur
Journal:  JCI Insight       Date:  2019-04-23

10.  Role of the T cell in the genesis of angiotensin II induced hypertension and vascular dysfunction.

Authors:  Tomasz J Guzik; Nyssa E Hoch; Kathryn A Brown; Louise A McCann; Ayaz Rahman; Sergey Dikalov; Jorg Goronzy; Cornelia Weyand; David G Harrison
Journal:  J Exp Med       Date:  2007-09-17       Impact factor: 14.307

View more
  1 in total

Review 1.  Hypertension: Do Inflammation and Immunity Hold the Key to Solving this Epidemic?

Authors:  Meena S Madhur; Fernando Elijovich; Matthew R Alexander; Ashley Pitzer; Jeanne Ishimwe; Justin P Van Beusecum; David M Patrick; Charles D Smart; Thomas R Kleyman; Justin Kingery; Robert N Peck; Cheryl L Laffer; Annet Kirabo
Journal:  Circ Res       Date:  2021-04-01       Impact factor: 17.367

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.